What Maiva Pharma does

Maiva Pharma (legal entity: Maiva Pharma Pvt. Ltd.) is a Bengaluru-headquartered, privately held Contract Development and Manufacturing Organization (CDMO) specializing in sterile liquid injectable formulations, including small-volume glass vials, ampoules, and large-volume glass bottles. Founded in 1996 and operating a manufacturing facility footprint of 501-1,000 employees, the company is recognized as India's second-largest pure-play injectables CDMO. Its customer base spans global pharmaceutical and biotechnology companies, with a strategic emphasis on regulated markets and the US hospital channel.

The company's core technical platform centers on advanced isolator-based sterile manufacturing systems, integrated in-house quality control and microbiology laboratories, and multi-format dosage capability spanning vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations. A new 22-acre manufacturing facility in Shoolagiri, Tamil Nadu was inaugurated in June 2026 with three commissioned manufacturing lines in Phase 1 and a planned expansion to six lines. Maiva's strategic US-market anchor is its manufacturing partnership with Breckenridge Pharmaceutical (a Towa International subsidiary) for sterile injectables serving US hospitals.

Maiva generates revenue through contract development and manufacturing fees earned under long-term supply agreements with pharmaceutical partners, a B2B model in which it manufactures products on behalf of clients who handle downstream commercialization and distribution. The company raised approximately INR 1,000 crores (~$120 million) in 2024 from Morgan Stanley Private Equity Asia and InvAscent's India Life Sciences Fund IV through primary and secondary funding, giving those sponsors a controlling stake. Leadership consists of Bhaskar Krishna as Managing Director and CEO.

Name

Maiva Pharma

Legal name

Maiva Pharma Pvt. Ltd.

Website

https://maivapharma.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Maiva Pharma is an Indian injectables CDMO and India's second-largest pure-play sterile injectable manufacturer, serving global pharmaceutical companies with vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations for regulated markets, especially the US hospital channel.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO / Sterile Injectable Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Sterile injectable manufacturing
• Pharmaceutical CDMO services
• Contract manufacturing organization
• Lyophilized formulations production
• Pre-filled syringe manufacturing

Headquarters

HQ city

Tiruchirappalli

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Contract Manufacturing Services: Maiva Pharma generates revenue as a Contract Development and Manufacturing Organization (CDMO), providing sterile injectable manufacturing services to pharmaceutical and biotechnology companies. The company develops and manufactures injectable products on behalf of clients, earning fees for manufacturing services typically under long-term supply agreements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Maiva Pharma operates as a pure-play injectables Contract Development and Manufacturing Organization (CDMO), specializing in the development and commercial manufacturing of sterile injectable dosage forms including vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations. The company serves global pharmaceutical and biotechnology partners with manufacturing capacity focused on regulated markets, particularly the US.

Product overview

Maiva Pharma is an Indian injectables CDMO (Contract Development and Manufacturing Organization) and India's second-largest pure-play injectables CDMO, based in Bengaluru. The company operates a 22-acre manufacturing facility in Shoolagiri, Tamil Nadu, with capabilities in sterile injectable dosage forms. Phase 1 of the facility features three dedicated manufacturing lines for vials, pre-filled syringes, cartridges, and lyophilized formulations using advanced isolator-based manufacturing systems. The company's core service offerings include sterile injectables manufacturing services for global regulated markets, with a strategic focus on the U.S. hospital market through its partnership with Breckenridge Pharmaceutical.

Differentiator

Problem solved

Functional benefit

Products and services

• Sterile Injectables Manufacturing Services
• US Hospital Market Sterile Injectables

Quantifiable outcome

• Phase 1 facility features three dedicated manufacturing lines with capacity to expand to six total lines

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Breckenridge PharmaceuticalcoreStrategic or Co-development Partner · 11 March 2026Strategic manufacturing partnership focused on sterile injectable products for the U.S. hospital market. Maiva serves as a key manufacturing partner for several injectable products, strengthening Breckenridge's position as a reliable supplier to hospitals and clinics nationwide. This collaboration represents a milestone in Breckenridge's evolution into specialty, hospital, and retail business lines.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Piramal Pharma Solutions: Piramal Pharma Solutions is an Indian CDMO with significant sterile injectable fill-finish capacity serving global regulated markets. Directly comparable as a domestic Indian sterile injectables CDMO targeting the same US/EU customer base.
• Aurobindo Pharma: Aurobindo is one of India's largest generic injectable manufacturers with US-approved facilities supplying the US hospital market. Highly comparable to Maiva in pure-play injectables and US-regulated market exposure.

Regional players

• Syngene International: Syngene is a leading Indian CRO/CDMO with biologics and small-molecule manufacturing, including sterile injectable capabilities. Comparable as an Indian-headquartered CDMO serving global pharma with regulated-market manufacturing.
• Hikal Ltd: Hikal is an Indian CDMO with API and finished dosage manufacturing including injectables. Comparable as an India-based contract manufacturer serving global pharma customers.

Broad incumbents

• Catalent: Catalent is a global CDMO with extensive sterile fill-finish capacity across vials, syringes, and cartridges. Comparable as a broad incumbent serving pharma customers in regulated markets with overlapping sterile injectable offerings.
• Lonza Group: Lonza is a global CDMO leader with aseptic fill-finish and sterile manufacturing capabilities for injectables. Comparable as a broad incumbent in sterile injectables CDMO serving global pharma and biotech customers.
• Recipharm: Recipharm is a European-headquartered CDMO with sterile injectable fill-finish services. Comparable as a broad incumbent in aseptic manufacturing serving regulated pharmaceutical markets.
• Aenova Group: Aenova is a European CDMO with sterile liquid and lyophilized injectable manufacturing capabilities. Comparable as a broad incumbent offering sterile fill-finish services to pharma partners in regulated markets.
• Thermo Fisher Scientific (Patheon CDMO): Thermo Fisher's Patheon CDMO business includes sterile injectable manufacturing services globally. Comparable as a broad incumbent with overlapping aseptic fill-finish and lyophilization capabilities.

Others

• Evonik Health Care: Evonik provides CDMO services including aseptic fill-finish for complex injectable formulations. Comparable as a contract manufacturer with overlapping sterile injectable capabilities serving pharma customers.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maiva Pharma